文献速递神经肌肉病

反义寡核苷酸BIIB078在C9orf72相关肌萎缩侧索硬化成人患者中的安全性、耐受性和药代动力学:一项1期、随机、双盲、安慰剂对照、多次递增剂量研究

Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study.
PubMed 文献 · Lancet Neurol · 2024-07-23

这项1期随机双盲安慰剂对照多次递增剂量研究在6国22个中心纳入106例C9orf72相关ALS成人患者,评估鞘内注射BIIB078的安全性、耐受性和药代动力学。所有受试者均发生至少1起不良事件,多数为轻中度;BIIB078组严重不良事件14/79例(18%),安慰剂组9/27例(33%)。因未见神经丝蛋白水平降低且临床结局相对安慰剂组无获益,BIIB078临床开发已终止。

要点

  • 所有受试者均发生至少1起不良事件,多数为轻中度且未导致治疗中止。
  • BIIB078组严重不良事件14/79例(18%),安慰剂组9/27例(33%)。
  • BIIB078组和安慰剂组分别有5例和3例发生致死性不良事件,报告研究者评估均与治疗无关。

核心结论

  • 基于这项1期研究结果,包括次要和探索性发现显示神经丝蛋白水平未见降低且临床结局相对安慰剂组无获益,BIIB078临床开发已终止。
  • 这些结果将有助于进一步理解C9orf72相关ALS复杂的病理生物学。

研究设计与样本

  • 1期、随机、双盲、安慰剂对照、多次递增剂量研究,在6个国家(加拿大、爱尔兰、荷兰、瑞士、英国和美国)的22个中心进行。
  • 纳入携带C9orf72致病性重复扩增的ALS成人患者,按队列3:1比例随机接受BIIB078或安慰剂,通过鞘内推注给药。
  • 队列1-6的BIIB078剂量分别为5 mg、10 mg、20 mg、35 mg、60 mg和90 mg;治疗期包括约每2周一次的三次负荷剂量,随后每月维持剂量,队列1-3治疗期约3个月,队列4-6约6个月。
  • 共筛查124例患者,排除18例,纳入并随机分配106例:BIIB078 5 mg组6例、10 mg组9例、20 mg组9例、35 mg组19例、60 mg组18例、90 mg组18例,安慰剂组27例;58例(55%)为女性。
  • 主要终点为不良事件和严重不良事件的发生率;试验注册号ClinicalTrials.gov NCT03626012,已完成。

主要发现

  • 所有受试者均发生至少1起不良事件,多数为轻中度且未导致治疗中止。
  • BIIB078治疗参与者中最常见的不良事件为跌倒、操作性疼痛、头痛和腰椎穿刺后综合征。
  • 接受任何剂量BIIB078的79例患者中14例(18%)报告严重不良事件,安慰剂组27例中9例(33%)报告严重不良事件。
  • BIIB078组5例和安慰剂组3例发生致死性不良事件:10 mg BIIB078组1例呼吸衰竭,35 mg BIIB078组2例ALS恶化和1例外伤性颅内出血,60 mg BIIB078组1例肺栓塞,安慰剂组3例呼吸衰竭;报告研究者评估所有死亡均与研究治疗无关。
  • 次要和探索性发现显示神经丝蛋白水平未见降低,临床结局相对安慰剂组无获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hexanucleotide repeat expansion of C9orf72 is a common genetic cause of amyotrophic lateral sclerosis (ALS). No C9orf72-targeted treatments are available. BIIB078 is an investigational antisense oligonucleotide targeting C9orf72 sense RNA. We aimed to assess the safety, tolerability, and pharmacokinetics of BIIB078 in participants with C9orf72-associated ALS. METHODS: This phase 1, randomised controlled trial was done at 22 sites in six countries (Canada, Ireland, Netherlands, Switzerland, UK, and USA). Adults with ALS and a pathogenic repeat expansion in C9orf72 were randomly assigned within six cohorts, via Interactive Response Technology in a 3:1 ratio per cohort, to receive BIIB078 (5 mg, 10 mg, 20 mg, 35 mg, 60 mg, or 90 mg in cohorts 1-6, respectively) or placebo, via an intrathecal bolus injection. The treatment period consisted of three loading doses of study treatment, administered approximately once every 2 weeks, followed by monthly maintenance doses during a treatment period of about 3 months for cohorts 1-3 and about 6 months for cohorts 4-6. Patients and investigators were masked to treatment assignment. The primary endpoint was the incidence of adverse events and serious adverse events. This trial was registered with ClinicalTrials.gov (NCT03626012) and is completed. FINDINGS: Between Sept 10, 2018, and Nov 17, 2021, 124 patients were screened for inclusion in the study. 18 patients were excluded and 106 participants were enrolled and randomly assigned to receive 5 mg (n=6), 10 mg (n=9), 20 mg (n=9), 35 mg (n=19), 60 mg (n=18), or 90 mg (n=18) of BIIB078, or placebo (n=27). 58 (55%) of 106 patients were female. All patients received at least one dose of study treatment and were included in all analyses. All participants had at least one adverse event; most adverse events were mild or moderate in severity and did not lead to treatment discontinuation. The most common adverse events in BIIB078-treated participants were falls, procedural pain, headache, and post lumbar puncture syndrome. 14 (18%) of 79 patients who received any dose of BIIB078 reported serious adverse events, compared with nine (33%) of 27 patients who received placebo. Five participants who received BIIB078 and three participants who received placebo had fatal adverse events: respiratory failure in a participant who received 10 mg BIIB078, ALS worsening in two participants who received 35 mg BIIB078, traumatic intracerebral haemorrhage in one participant who received 35 mg BIIB078, pulmonary embolism in one participant who received 60 mg BIIB078, and respiratory failure in three participants who received placebo. All deaths were assessed as not related to the study treatment by the reporting investigator. INTERPRETATION: On the basis of these phase 1 study results, including secondary and exploratory findings showing no reduction in neurofilament levels and no benefit on clinical outcomes relative to the placebo cohort, BIIB078 clinical development has been discontinued. However, these results will be informative in furthering our understanding of the complex pathobiology of C9orf72-associated ALS. FUNDING: Biogen.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. van den Berg LH, Rothstein JD, Shaw PJ, et al. Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. Lancet Neurol. 2024. PMID: 39059407. doi:10.1016/S1474-4422(24)00216-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。